Iron chelation therapy needed for serum ferritin overloaded patients of beta thalassemia major
The main objective of the current study is to evaluate the level and overload of serum ferritin in multi-transfused beta Thalassemia major patients. There is an earnest need to defend the chelation treatment and to make mindfulness about the results of serum ferritin in the patients beta Thalassemia major. This is a Cross sectional analytical study performed in Fatimid foundation Hayatabad, Peshawar, Khyber Pakhtunkhwa province of Pakistan. Those patients who has beta thalassemia major are included in this study. In this study there are total 108 patients in which 54 males and 54 females. The highest mean of serum ferritin level in the category of male was in the age of 12 years were finds 8160.5 ng/mL. Among the female the highest mean of ferritin level was in the age of 17 years were finds 13,349.5 ng/mL. In this study majority of patient’s revealed much high levels of serum ferritin. These levels reveal insufficient chelation. Appropriate chelation of iron load can improve the quality of the life of these patients. The low level of education, Poverty problems, and insufficient health care facility of are the main obstacle in the effective management of ferritin overload in thalassemia patients.
Ghodekar SR, Grampurohit ND, Kadam SS, Thorat RM. Thalassemia: A review. Int J Pharma Res Develop 2010;2:101-8.
Ikram N, Hassan K, Younas M, Amanat S. Ferritin levels in patients of beta thalassaemia major. Int J Pathol 2004;2:71-4.
Medline Plus. Thalassemia: MedlinePlus Medical Encyclopedia [Internet]; 2015. Available from: http://www.nlm.nih.gov/medlineplus/ency/article/000587.htmlopedia
Thalassemia_Types, symptoms, and treatment. Available from: https://www.medicalnewstoday.com/articles/263489
Cappellini MD, Piga A. Current status in iron chelation in hemoglobinopathies. Curr Mol Med 2008;8:663-74.
Vogiatzi MG, Macklin EA, Fung EB, et al. Bone disease in thalassemia: a frequent and still unresolved problem. J Bone Mineral Res 2009;24:543-57.
Mayo Clinic [Internet]. Symptoms and causes - Enlarged spleen (splenomegaly). Available from: http://www.mayoclinic.org/diseases-conditions/enlarged-spleen/symptoms-causes/dxc-20214722
Soliman A, De Sanctis V, Elsedfy H, et al. Growth hormone deficiency in adults with thalassemia: an overview and the I-CET recommendations. Georgian Med News 2013;222:79-88.
Thalassemia syndromes_Lifeline Laboratory. Available from: https://ypteqadcxjmwldou.quora.com/THALASSEMIA-SYNDROMES-Article-By-Lifeline-Laboratory?ch=1&share=05d7cd5f
Thalassaemia Federation of Pakistan. Available from: http://tfp.org.pk/
Ferritin Level Blood Test_ Purpose, Procedure, and Results. Available from: https://www.webmd.com/a-to-z-guides/ferritin-blood-test
Transfusion hemosiderosis - Wikipedia. Available from: https://en.wikipedia.org/wiki/Transfusion_hemosiderosis
Institute ID. Iron Disorders Institute [Internet]. Tests To Determine Iron Levels; 2009. Available from: http://www.irondisorders.org/iron-levels-tests
Shah R, Trehan A, Das R, Marwaha RK. Serum ferritin in thalassemia intermedia. Indian J Hematol Blood Transf 2014;30:281-5.
Pakbaz Z, Fischer R, Fung E, et al. Serum ferritin underestimates liver iron concentration in transfusion independent thalassemia patients as compared to regularly transfused thalassemia and sickle cell patients. Pediatr Blood Cancer 2007;49:329-32.
Hoffbrand AV, Cohen A, Hershko C. Role of deferiprone in chelation therapy for transfusional iron overload. Blood 2003;102:17-24.
Galanello R. Iron chelation: New therapies - Semin Hematol 2001;38:73-6.
Giardina PJ, Grady RW. Chelation therapy in beta-thalassemia: an optimistic update. Semin Hematol 2001;38:360-6.
Khan MZ, Khan S, Khan A, et al. Serial serum ferritin levels for monitoring response to iron chelation therapy in patients of beta thalassemia major “Prospective cohort study”. KJMS 2014;7:245.
Rajish IM, Sumje KW, Butul M, Khan MA. Route of administration of iron chelators-an important factor for patient adherence and acceptance in multi transfused thalassemia major patients. J Basic Appl Sci Res 2014;4:61-70.
Cappellini MD, Cohen A, Piga A, et al. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with β-thalassemia. Blood 2006;107:3455-62.
Guideline_Iron chelation treatment - Ithapedia. Available from: https://thalassemia.com/treatment-chelation.aspx#gsc.tab=0
Uygun V, Kurtoglu E. Iron-chelation therapy with oral chelators in patients with thalassemia major. Hematology 2013;18:50-5.
Galanello R. Deferiprone in the treatment of transfusion-dependent thalassemia: a review and perspective. Therap Clin Risk Manage 2007;3:795.
Agarwal MB, Gupte SS, Viswanathan C, et al. Long‐term assessment of efficacy and safety of L1, an oral iron chelator, in transfusion dependent thalassaemia: Indian trial. Br J Haematol 1992;82:460-6.
Al-Refaie FN, Wonke B, Hoffbrand AV, et al. Efficacy and possible adverse effects of the oral iron chelator 1, 2-dimethyl-3-hydroxypyrid-4-one (L1) in thalassemia major [see comments]. Blood 1992;80:593-9.
- Abstract views: 340
- PDF: 80
Copyright (c) 2021 the Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.